Druggio Logo

Druggio

Allergic rhinitis

Allergic rhinitis (AR) is an inflammation of nasal mucosa mediated by IgE-associated processes, which is characterised by pruritus, sneezing, rhinorrhoea, and nasal congestion. The development of AR entails a complex interaction between genetic predisposition and environmental exposure to different factors, of which the most important is the implicated allergen. Single-nucleotide polymorphism studies involving genes encoding for molecules implicated in the pathogenesis of AR have also been made. Such molecules comprise chemokines and their receptors, interleukins and their receptors, eosinophil peroxidase and leukotrienes, among others.

Drugs that treat Allergic rhinitis

Rupafin

Approval date

2017/9/27

Bilanoa

Approval date

2016/9/28

Desalex

Made by

MSD

Approval date

2016/9/28

Xyzal

Approval date

2010/10/27

Erizas

Approval date

2009/10/16

Allermist

Approval date

2009/4/22

Xolair

Made by

Novartis

Approval date

2009/1/21

Nasonex

Made by

MSD

Approval date

2008/7/16

Claritin

Made by

MSD

Approval date

2002/7/5

Allelock

Made by

Kyowa Kirin

Approval date

2000/12/22

Allegra

Made by

Sanofi

Approval date

2000/9/22

Livostin

Approval date

2000/9/22

Talion

Approval date

2000/7/3

Baynas

Made by

Bayer

Approval date

2000/3/10